The analyst's clinical trial report, “Reflux Esophagitis (Gastroesophageal Reflux Disease) - Global Clinical Trials Review, 2025" provides an overview of Reflux Esophagitis (Gastroesophageal Reflux Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Reflux Esophagitis (Gastroesophageal Reflux Disease). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)
- Oct 20, 2025: Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Poster at AASLD The Liver Meeting 2025
- Oct 15, 2025: Rivus Pharmaceuticals To Present Clinical Data From Phase 2A M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD 2025
- Oct 07, 2025: Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting 2025
- Oct 07, 2025: Akero Therapeutics To Present New Data From the Phase 2B Symmetry and Harmony Studies of Efruxifermin at the 76th Annual AASLD the Liver Meeting 2025
- Oct 07, 2025: Sagimet Biosciences Announces Upcoming Presentation at AASLD-the Liver Meeting 2025
- Oct 07, 2025: Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
- Oct 06, 2025: Eccogene Receives U.S. FDA Clearance To Initiate Phase 2A Mosaic Trial of ECC4703 for MASH
- Oct 06, 2025: Eccogene Receives U.S. FDA Clearance To Initiate Phase 2A MOSAIC Trial of ECC0509 for MASH
- Oct 01, 2025: Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
- Sep 17, 2025: Positive Phase 3 Results for Denifanstat for the Treatment of Moderate To Severe Acne To Be Presented at the EADV Congress 2025 by Partner Ascletis
- Sep 02, 2025: Biomed Industries to Present Pivotal Studies on NA-931 at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies
- Sep 02, 2025: Biomed Industries to Present Pivotal Studies on NA-941 at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies
- Aug 14, 2025: Akero Announces Publication of Phase 2b Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
- Aug 12, 2025: Sen-Jam Pharmaceutical Positions SJP-002C as a Transformative Complement to GLP-1 Therapies and a Standalone Solution for MASH
- Aug 11, 2025: Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Source
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Region, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, North America, Top Countries, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
- Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Phase, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Region (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
- Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Phase (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Takeda Pharmaceutical Co Ltd
- AstraZeneca Plc
- Daewoong Co Ltd
- Eisai Co Ltd
- Johnson & Johnson
- Pfizer Inc
- Dr. Reddy's Laboratories Ltd
- Reckitt Benckiser Group Plc
- Krka dd Novo Mesto
- Thermo Fisher Scientific Inc
